


Toward Fully Automated High Performance Computing Drug Discovery: A Massively Parallel Virtual Screening Pipeline for Docking and Molecular Mechanics/Generalized Born Surface Area Rescoring to Improve Enrichment

Xiaohua Zhang, Sergio E. Wong, and Felice C. Lightstone*

Biosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Lab, Livermore, California 94550

S Supporting Information

ABSTRACT: In this work we announce and evaluate a high throughput virtual screening pipeline for *in-silico* screening of virtual compound databases using high performance computing (HPC). Notable features of this pipeline are an automated receptor preparation scheme with unsupervised binding site identification. The pipeline includes receptor/target preparation, ligand preparation, VinaLC docking calculation, and molecular mechanics/generalized Born surface area (MM/GBSA) rescoring using the GB model by Onufriev and co-workers [*J. Chem. Theory Comput.* **2007**, *3*, 156–169]. Furthermore, we leverage HPC resources to perform an unprecedented, comprehensive evaluation of MM/GBSA rescoring when applied to the DUD-E data set (Directory of Useful Decoys: Enhanced), in which we selected 38 protein targets and a total of ~0.7 million actives and decoys. The computer wall time for virtual screening has been reduced drastically on HPC machines, which increases the feasibility of extremely large ligand database screening with more accurate methods. HPC resources allowed us to rescore 20 poses per compound and evaluate the optimal number of poses to rescore. We find that keeping 5–10 poses is a good compromise between accuracy and computational expense. Overall the results demonstrate that MM/GBSA rescoring has higher average receiver operating characteristic (ROC) area under curve (AUC) values and consistently better early recovery of actives than Vina docking alone. Specifically, the enrichment performance is target-dependent. MM/GBSA rescoring significantly out performs Vina docking for the folate enzymes, kinases, and several other enzymes. The more accurate energy function and solvation terms of the MM/GBSA method allow MM/GBSA to achieve better enrichment, but the rescoring is still limited by the docking method to generate the poses with the correct binding modes.



INTRODUCTION

Accurately and efficiently predicting the binding affinities of putative protein–ligand complexes is crucial for structure-based drug virtual screening.^{1,2} Molecular docking methods with various scoring functions are usually employed to access the binding affinities between compounds and drug targets in the early stage of structure-based drug design.^{3,4} To achieve high throughput, the scoring functions often use less computationally intensive methods, such as molecular mechanics force-field methods, empirical scoring functions, and/or knowledge-based potentials.^{5,6} The scoring functions often simplify the calculation by neglecting important terms that are known to influence the binding affinity, such as, solvation, entropy, receptor flexibility, etc.^{7,8} A very popular practice is to rescore top-ranking docking poses using more accurate, albeit computationally costly, methods to overcome shortcomings in the docking scoring function.^{9–12}

Solvation effects, mainly contributed by water molecules in the biological systems, play a critical role in ligand binding by providing bulk solvent stabilization and solute-desolvation, increasing the entropic contribution with the release of water molecules in the active site upon binding, serving as molecular bridges between the ligand and receptor, etc.^{13,14} There are two main molecular mechanical (MM) models to simulate water: explicit¹⁵ and implicit/continuum solvent models.¹⁶ Explicit water models treat solvent by including individual water molecules, while implicit models represent water as a homogeneous dielectric. The continuum model is much less computationally expensive than the explicit model, which makes it an ideal method to carry out the rescoring of an enormous number of docking poses. Numerically solving the Poisson–Boltzmann (PB) equation yields the electrostatic

Received: September 4, 2013

Published: December 20, 2013

potential for a given system. Another popular approach is to use the Generalized Born (GB) model, which is typically parametrized on the PB results.

Combining molecular mechanics and implicit solvent models, molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) and molecular mechanics/generalized Born surface area (MM/GBSA) have been widely applied to calculate the free energy of binding for ligand–receptor complexes.^{17–20} Compared to other free energy methods, such as free energy perturbation and thermodynamic integration methods, the MM/PB(GB)SA method is much less computationally intensive. As a standard protocol, the MM/PB(GB)SA method has been implemented in many molecular mechanics simulation packages, e.g. Amber,^{21,22} CHARMM,²³ Gromacs,²⁴ etc. In recent years, many reviews have been published on the development and progress of the implicit solvent model and the MM/PB(GB)SA method.^{25–31} Chen et al. have optimized atomic radii and protein backbone torsional parameters of implicit solvent models to better match potentials of mean force (PMF) calculated from explicit solvent free energy simulations.³² Explicit solvent molecules have been added to the continuum solvent calculations by Kelly and co-workers for the calculation of aqueous acid dissociation constants.³³ Accurate absolute solvation free energies of small molecules using an implicit solvent model have been calculated with an automated protocol developed by the Roux group.³⁴ A GB model is extended by the molecular volume correction term by Mongan et al., which largely corrects the solvent-excluded volume of each pair of atoms.³⁵ A new GB model, developed by Labute, estimates the free energy of hydration using London dispersion instead of atomic surface area.³⁶

In this work we report (1) the development of an automated pipeline to prepare, dock and rescore protein–ligand complexes and (2) a very large-scale validation of the GB model developed by Onufriev and co-workers³⁷ for the purposes of enrichment in virtual screening experiments. The accuracy of poses and binding free energies for the Onufriev et al.³⁷ MM/GBSA method was investigated by Hou et al.^{38–40} Here, we focus on enrichment of binders versus nonbinders using MM/GBSA rescoring. Huang and colleagues⁴¹ have reported on a combination of docking and rescoring of nine protein targets with a modest pool of actives and decoys. However, to the best of our knowledge, there are no reports that systematically study the enrichment factor of the rescoring method on large databases with a variety of targets and thousands to millions of actives and decoys. In this article, we are able to perform such a study by leveraging the high performance computing (HPC) resources at Lawrence Livermore National Laboratory and with our in-house developed fully automated high throughput virtual screening pipeline. The docking and rescoring results of the Directory of Usefully Decoys Enhanced (DUD-E) data set,⁴² as calculated by the VinaLC docking program⁴³ and our in-house rescoring protocol, are presented in this study.

METHOD

Workflow of Docking and Rescoring. The workflow of the fully automated high throughput virtual screening pipeline is shown in Figure 1. The overall workflow is to treat the receptors/targets and ligands by the programs, preReceptors, and preLigands, respectively. Then, complexes are generated by docking the ligands into the active sites of receptors/targets using the VinaLC docking program.⁴³ The top 20 docking




Figure 1. Flowchart of docking and rescoring.

poses of each complex are rescored with MM/GBSA and reranked by their calculated binding free energies.

The detailed procedures involved in the workflow are described as follows. For the receptors, the raw PDB files are processed by our in-house program to identify active sites.^{44,45} The structures of the receptors are protonated, and the centroids of the active sites/binding sites are determined. These pretreated receptor structures are used as input for the preReceptor program. The preReceptor program first determines the dimensions of docking grids by utilizing the dms⁴⁶ and sphgen programs.⁴⁷ The dms program calculates the molecular surface of the receptor, and the sphgen program fills the active site of the receptor with spheres. In order to reduce the computer time, the receptor is cut at a radius of 30 Å from the centroid of active site. The dimensions of docking grids are determined by finding the distribution of spheres along the X-, Y-, and Z-axis. The cutoffs are set when the distribution of spheres changes drastically. The dimensions of the docking grids and centroid of the active site are stored for docking calculations in the next step. The Amber forcefield f99SB⁴⁸ is employed in the calculation for the receptor. Any nonstandard amino acids that are not present in the active site are converted to alanine. If present in the active site, the nonstandard amino acids are precalculated and stored in the library. Energy minimization of the receptor is carried out using the MM/GBSA implemented in the Sander program of the Amber package.²¹ Energy minimization is separated into two steps: (1) the structures are minimized with heavy atom constraints and (2) then all the constraints are removed. The PDB files of energy-minimized receptor structures are converted to PDBQT files, which are used in the docking procedure. During the conversion, nonpolar hydrogen atoms are removed from the receptor structures. Ligands use the Amber GAFF forcefield⁴⁹ as determined by the antechamber program⁵⁰ in the Amber package. Partial charges of ligands are calculated using the AM1-BCC method.⁵¹ The structures of ligands are energetically minimized by the MM/GBSA method implemented in Sander. The atomic radii developed by Onufriev and co-workers (Amber input parameter *igb* = 5) are chosen for all GB calculations.³⁷ Those atoms with GB radii missing from the




Figure 2. Pipeline and time scales for the docking and MM/GBSA rescoring calculations. The time scales are calculated from an example with a target of about 4000 atoms and about 40 000 ligands. The top 20 docking poses are rescored using the MM/GBSA method.

original program (i.e., fluorine, using a GB radius of 1.47 Å) are added into the Sander program. The PDB files of energy-minimized ligand structures are converted to multiple-structure PDBQT files. As with the receptors, nonpolar hydrogen atoms are removed from the ligand structures.

The VinaLC parallel docking program is employed to generate ligand–receptor complexes from a list of receptors and a list of ligands. The docking grid granularity is set to 0.333 Å. The exhaustiveness is set to 12, so that 12 Monte Carlo simulations for searching docking poses are run for each complex. The top 20 docking poses of each ligand are saved for the rescoring step.

Because the nonpolar hydrogen atoms have been removed from the ligands before the docking calculations, they are regenerated using the tleap program in the Amber package, according to the Amber forcefield, and saved in PDB files in preparation for the MM/GBSA rescoring procedure. The PDB files of the ligand and its corresponding receptor are concatenated into one PDB file, which is the PDB file for the complex. Energy minimization is performed for the complex with the receptor portion constrained and using the MM/GBSA method. The final total energy of the complex, excluding the constraint energy, is extracted. The final total energies of the ligand and receptor are also extracted from the previous calculation. The final total energy includes standard energy terms with two additional terms, GB and surface energies, calculated by the MM/GBSA method. The binding free energy is calculated from the final total energy of the complex, subtracting those of the ligand and the receptor. The top 20 docking poses are reranked based on the resulting binding free energy.

Code Implementation. On the basis of the workflow (Figure 1), four parallel programs, preReceptors, preLigands, VinaLC, and mmgbasa have been developed to perform the calculations at different steps (Figure 2). VinaLC uses an MPI and multithreading hybrid scheme, which has been previously described.⁴³ For the other three programs, they have a similar design that contains an MPI framework and provides interfaces to call applications in the Amber package in order to calculate a massive number of ligands, receptors, and complexes in parallel on the HPC machines.

The MPI framework employs a master–slave scheme as illustrated in Figure 2. The master process is shown on the left

side, and the slave processes are on the right. The master process is in charge of job dispatching, input/output data handling, job tracking, etc. The slave processes receive the input data from the master, perform the actual calculation, and send the results/error messages to the master for output. The master process goes through every combination of the receptor and ligand. The master process tries to receive the rank of any free slave process. If there are still jobs in the queue, the master process sends an unfinished job flag to the free slave process. All the input and output data are handled by the master process. The input data are packed into one data package so that only one pair of MPI send/recv calls is required, to reduce the MPI overhead. The output data are treated with the same approach. The master process sends the input data required for the docking or rescoring calculations to the slave process. After receiving the input data, the slave process performs the calculation. The slave process sends the output data back to the master process when it finishes the assigned calculation from the master process. Only after the master process has assigned each slave process with a docking calculation will the master process start collecting the output data. Once the output data from the slave process is collected, then the master process will give that slave process another job. When there are no jobs left in queue, the master process sends a finished job flag to free the slave processes. By implementing such a master–slave MPI scheme, the master is in charge of job dispatching, input, and output while the slave processes are kept busy by running individual calculations until all the calculations are finished. In the slave process, the interfaces to the applications in the Amber package are implemented and are wrapped with try-catch clauses to catch any error that could arise from the calculation. Those errors are passed to the master process and stored in the job-tracking file in XML format. The master node will also track the status of the completed jobs. This information is also saved in the job-tracking XML file.

The program currently supports Linux, IBM BG/Q, and Mac OS operating systems and relies on two external libraries, Boost and MPI. Typical commands to run the workflow, using preReceptors, preLigands, VinaLC, and mmgbasa programs with a SLURM⁵² job schedule, are




Figure 3. Scheme of ROC plots. The scheme depicts four different scenarios: (1) ideal performance with actives always ranking better than decoys; (2) good performance with most of actives ranking better than decoys; (3) random performance with both actives and decoys ranking equally; (4) bad performance with most of decoys ranking better than actives. The ROC plots of scenarios 2, 3, and 4 are shown on the right.

```

srun -N50 -n800 preReceptors
      --recList recList.txt [--xml jobtrack]

```

```

srun -N80 -n960 preLigands
      --sdf ligand.sdf [--xml jobtrack]

```

```

srun -N1284 -n1284 -c12 vinaLC
      --recList recList.txt --ligList ligList.txt
      --geoList geoList.txt [--exhaustiveness 12]
      --granularity 0.333 --num_modes 20]

```

```

srun -N1284 -n15408 mmgbsa --recList recList.txt
      --ligList ligList.txt [--xml jobtrack]

```

where the flags in “[]” are optional. The default values are used, if these options are not present. The combination of four commands performs the docking and MM/GBSA rescoring of the ligands in “ligand.sdf” against targets in the “recList.txt”.

Benchmark Data Set. The DUD data set is a very popular data set in benchmarking docking programs.^{43,53} The original DUD data set has 40 protein targets, 2950 actives overall, and 36 decoys on average for each active. Recently, an upgraded version data set, DUD-E, has been released by Irwin et al.,⁴² with a total of 102 protein targets, 22 886 actives overall, and 50 decoys on average for each active. The new DUD-E data set improves chemotype diversity, decreases net formal charge imbalance between actives and decoys, eliminates the false decoys, etc. In our previous study, we used the DUD data set to benchmark the VinaLC docking program and compared to other popular docking programs, such as DOCK 3.6, Glide, etc.⁴³ With the new DUD-E data set available, we selected 38 protein targets, which are included in both the original DUD and new DUD-E data set, so that we are confident about the performance of our docking protocol on this data set. In the DUD-E data set, platelet-derived growth factor receptor β was

dropped because it is a homology model. Estrogen receptor α (esr1) is a single target in DUD-E; whereas, it was split into agonists and antagonists previously. The new actives and decoys of those 38 protein targets in the DUD-E data set were employed in benchmarking our docking-rescoring pipeline. In other words, a subset of DUD-E data set with 38 targets has been employed in our study. It should be pointed out that the ratio of decoys to actives has changed from 36 to 50 between the old DUD data set and new DUD-E data set, respectively. In addition, the numbers of both actives and decoys has also increased for each of the proteins in the DUD-E data set. Thus, one should expect that the numbers for the early recovery of actives in this study should be smaller than those in the previous paper.⁴³ Unless otherwise mentioned, the DUD-E data set in the following paragraphs refers to the selected subset of the DUD-E data set with only 38 targets. Specifically, the subset contains the following protein targets: androgen receptor (andr), estrogen receptor alpha (esr1), glucocorticoid receptor (gcr), mineralocorticoid receptor (mcr), peroxisome proliferator-activated receptor gamma (pparg), progesterone receptor (prgr), retinoid X receptor alpha (rxra), cyclin-dependent kinase 2 (cdk2), epidermal growth factor receptor erbB1 (egfr), fibroblast growth factor receptor 1 (fgfr1), heat shock protein HSP 90-alpha (hs90a), MAP kinase p38 alpha (mk14), tyrosine-protein kinase SRC (src), thymidine kinase (kith), vascular endothelial growth factor receptor 2 (vgfr2), coagulation factor X (fa10), thrombin (thrb), trypsin I (try1), dihydrofolate reductase (dyr), GAR transformylase (pur2), angiotensin-converting enzyme (ace), adenosine deaminase (ada), catechol O-methyltransferase (comt), phosphodiesterase 5A (pde5a), acetylcholinesterase (aces), aldose reductase (aldr), beta-lactamase (ampc), cyclooxygenase-1 (pgh1), cyclooxygenase-2 (pgh2), muscle glycogen phosphorylase (pygm), HIV-1 protease (hivpr), HIV-1 reverse transcriptase (hivrt), HMG-CoA reductase (hmdh), enoyl-[acyl-carrier-protein] reductase (inha), neuraminidase (nram), poly [ADP-ribose] polymerase-1 (parp1), purine nucleoside phosphorylase (pnph), and adenosylhomocysteinase (sahh).




Figure 4. Bar graphs of the AUC values for the ROC curves of the DUD-E targets. The blue bars are the AUC for Vina docking, and the red ones are for MM/GBSA rescoring. The graphs are arranged according to the enzyme type.

The MM/GBSA method is used for rescoring. In some extremely rare cases, some single point MM/GBSA energy minimizations could not converge and are excluded from the final results. Docking scores and MM/GBSA rescoring values are directly compared head-to-head in this study. Some ligands in the DUD-E data set have multiple structures due to chirality and/or tautomerization. For the MM/GBSA method, only one structure associated with the lowest binding free energy is used in the final results. For the Vina docking method, only one structure associated with the top Vina docking score is used in the final results.

Enrichment Factor. There are many ways to gauge the enrichment performance of the program. Enrichment factor (EF)^{54–56} is one of methods that is used to measure the virtual screening performance of the VinaLC docking program.⁴³

$$EF^{x\%} = \frac{\text{actives}_{\text{sampled}}}{\text{actives}_{\text{total}}} \frac{N_{\text{total}}}{N_{\text{sampled}}}$$

where $\text{actives}_{\text{sampled}}$ is the number of actives found at $x\%$ of the screened database, $\text{actives}_{\text{total}}$ is the number of total actives in the database, N_{sampled} is the number of compounds at $x\%$ of database, and N_{total} is the number of total compounds in the database. The enrichment factor has several deficiencies because it largely depends on the composition of the data set and is not stable at low $x\%$. Thus, in this study we used the average value of EF calculated from 38 targets in the DUD-E data set in order to eliminate the variability of data composition and reduce the uncertainty of the value at low $x\%$. The EF values were calculated in two approaches: one uses the VinaLC score and other uses the MM/GBSA binding free energy.

Receiver Operating Characteristic (ROC) Plot. The receiver operating characteristic (ROC) plot is employed in this study for measuring virtual screening performance.^{57–59} Figure 3 shows four different scenarios for ranking the actives and decoys according to either docking scores or MM/GBSA rescoring scores. In the first scenario, ideally, actives always rank better than the decoys, which yields ideal performance. In

the second scenario, most of actives rank better than decoys, which yields good performance. The fraction of the actives and decoys are calculated when they are selected sequentially from the rank of their own collections (Figure 3). The ROC curve is plotted according to the fractions for the decoys and actives on the x - and y -axis, respectively. The ROC curve is above the diagonal line and the area under the curve (AUC) is greater than 0.5 in this scenario. In the third scenario, the actives and decoys rank equally, which yield random-selection performance. The ROC curve crawls along the diagonal line, and the AUC value is near 0.5. In the fourth and worse scenario, most decoys rank better than actives, which yields bad performance. The ROC curve is under the diagonal line, and the AUC value is less than 0.5. The ROC method can effectively differentiate two populations so that it can be applied to differentiate the actives against the nonactive decoys and reveal the enrichment performance of the docking and rescoring methods.

RESULTS AND DISCUSSION

Enrichment Performance Improvement by MM/GBSA Rescoring. A total of 38 targets with their actives and decoys from the DUD-E data set have been processed through the high throughput virtual screening pipeline. The plots of ROC curves for all 38 targets are shown in the Supporting Information (Figure 1S). The ROC plots are arranged in sequence of 7 nuclear hormone receptors, 8 kinases, 3 serine proteases, 4 metalloenzymes, 2 folate enzymes, and 14 other protein targets.⁵³ The AUC values of the ROC curves were calculated and are listed in the Supporting Information (Table 1S). They are plotted and shown in barplots for comparison (Figure 4). Examining the enrichment performance from the perspective of enzyme classes shows that the enrichment performance between docking and free energy methods is dependent on the enzyme class. For folate enzymes and kinases, the MM/GBSA method significantly out performs the docking method in most cases. For the nuclear hormone receptors, the AUC values for docking and free energy

rescoring are similar and have good enrichment performance. For the serine proteases, docking scores slightly out-performs the free energy rescoring. Both the docking and free energy method have poor enrichment performance against metalloenzymes. For the remaining enzymes, the MM/GBSA rescoring method outperforms the docking enrichment in 11 out of 14 enzymes. The average AUC value from all 38 targets for Vina docking is 0.66, and the MM/GBSA rescoring method improves the AUC to 0.71, on average. Free energy rescoring differentiates the actives from the nonactive decoys better than Vina docking. The average enrichment factors for all 38 targets at 0.5%, 1%, 2%, 5%, and 10% are shown in Table 1. The

Table 1. Enrichment Factor Average from 38 DUD-E Targets

method	0.5%	1%	2%	5%	10%
Vina	10.78	7.48	5.54	4.05	2.81
MM/GBSA	12.94	8.99	7.70	5.30	3.68

enrichment factors of the MM/GBSA rescoring at each of the percentages are consistently larger than their counterparts from Vina docking. Thus, the early recovery of actives for MM/GBSA rescoring is consistently better than that of Vina docking alone. Many previous efforts using MM/GBSA rescoring^{9,38–40,60–62} have been spent on pursuing better correlation between the calculated binding free energies and experimental p*K*_i or p*IC*₅₀ or finding structural accuracy of poses. Our study systematically demonstrates with an array of various classes of proteins that free energy rescoring on average improves the enrichment performance.

Kinases. The DUD-E data set has 8 kinases as shown in Figure 4. One of the most significant performance differences between docking and free energy rescoring is with target hs90a. Target hs90a is the N terminal domain of heat shock protein (PDB ID: 1UYG), which contains a hydrophobic binding site.⁶³ Residues 104–111 adopt a helical conformation that is mainly hydrophobic in nature. In most cases, the aromatic rings of complexed ligands are stacked between the side chains of Phe138 and Leu107. Figure 5A shows the X-ray crystal ligand (8-(2,5-dimethoxy-benzyl)-2-fluoro-9h-purin-6-ylamine) in the active site of target hs90a as a reference. The ROC plot of hs90a shows the enrichment performance calculated from the Vina score is significantly worse than random selection with an AUC of 0.19, while the enrichment performance calculated from the MM/GBSA rescoring is better than random selection with an AUC of 0.56 (Figure 1S and Figure 4 hs90a). Only 17% of the ligands (both actives and decoys) select identical docking poses for the Vina score and MM/GBSA rescoring. About 37% of the decoys have Vina scores better (less) than −9.0 kcal/mol while that for actives is only 12%. Overall, the decoys have unusually better Vina scores than the actives. Investigating the poses of decoys selected by docking and MM/GBSA rescoring, we found several types of docking poses that have consistent discrepancies, such as displacement from the active site, solvation effects, and overestimation of interactions. In the first case, Vina-selected docking poses that prefer a different binding pocket. Decoy ZINC51634301, shown in Figure 5, clearly illustrates this problem. The docking pose has the ligand bound in a nearby tight pocket, completely displacing the ligand such that the ligand is no longer bound in the active site as defined by the crystal ligand, that is also shown in the same figure for comparison (Figure 5A). The free energy pose has




Figure 5. Poses of the Decoy ZINC51634301 in the active site of target hs90a: (A) docking pose (cyan) aligned with crystal ligand (yellow) and (B) MM/GBSA rescoring pose (magenta) aligned with crystal ligand (yellow).

the ligand bound in the original active site similar to the X-ray crystal ligand (Figure 5B). Obviously, the Vina docking method has picked the wrong binding mode, which can be attributed to the underestimation of the repulsion terms in the Vina scoring function. Judging from their ranking, the rank of Decoy ZINC51634301 from the docking pose is 265 out of a total of 5067 actives and decoys and that for the MM/GBSA-selected pose is 1350 out of 5067, which shows that the decoy has been ranked significantly higher by the docking score. Similar cases can be found for Decoy ZINC47325294, ZINC44153979, ZINC10001939, and ZINC07613880. The second discrepancy between docking and free energy poses is related to solvation. Decoy ZINC12707283, which has two carbonyl groups (Figure 6), exemplifies this issue. The carbonyl groups of the docking pose are pointed into the hydrophobic active site while those of the MMGBSA-selected pose are exposed to bulk water. The Vina score ranks this decoy 1691 out of a total of 5067 actives and decoys while free energy rescoring ranks it merely 3751. Chemically, a carbonyl group is hydrophilic and should interact favorably with water. Thus, this type of discrepancy is likely due to an improved treatment of solvent by the GB model. Similar examples can be found in many other decoys, such as Decoy ZINC45513233 and ZINC16525498. The third difference is specific to aromatic ring–ring interactions energies. Decoy ZINC39856096 has seemingly similar poses for both docking and free energy calculations. After energy minimization, the MM/GBSA rescoring selected structure deviates only slightly from the original Vina docking pose as shown in Figure 7. Structurally, there is no significant difference between the Vina and MM/GBSA methods. However, the interaction energy is significantly different. The MM/GBSA binding energy of Decoy ZINC39856096 puts the rank at the lowly position of 4162 out of a total of 5067 actives and decoys, while docking ranks the decoy 811 out of 5067. After careful examination of




Figure 6. Poses of the Decoy ZINC12707283 in the active site of target hs90a: (A) docking pose; (B) MM/GBSA rescoring pose. The surfaces of protein are colored according to the hydrophobicity. The hydrophobicity decreases from yellow to blue.




Figure 7. Poses of the Decoy ZINC39856096 in the active site of target hs90a. The carbon atoms of docking and MM/GBSA selected poses are colored in cyan and magenta, respectively.

the complex structure, the Vina scoring function seems to overestimate the ring stacking effects between the side chains of Phe138 and Leu107, which may due to the overestimation of van der Waals effects (Figure 7). Similar to Decoy ZINC39856096, the docking score of Decoy ZINC39356214 ranks the ligand fairly high in the actives (456 out of 5067), while the free energy method ranks the ligand relatively low in the actives (3192 out of 5067). Also similar to Decoy ZINC39856096, Decoy ZINC39356214 has a phenyl ring but also has an additional quinazolinone ring (Figure 8). The MM/GBSA-selected pose prefers the quinazolinone ring stacking between the side chains of Phe138 and Leu107, while the docking pose has the phenyl ring stacking between them. The Vina scoring function prefers the homocyclic aromatic ring to the heterocyclic one for ring stacking. Overall, for target hs90a, the free energy method picks the correct pose as compared to Vina docking.




Figure 8. Poses of the Decoy ZINC39356214 in the active site of target hs90a: (A) Vina selected pose; (B) MM/GBSA selected pose.

Another kinase, tyrosine-protein kinase (target src), has a highly conserved glutamic acid residue within a deep hydrophobic binding pocket that interacts with an amide/urea linker connecting the hydrophobic portions of the inhibitors.⁶⁴ This interaction is a key feature to inhibitor binding. In general the inhibitors have different solvent properties compared to the decoy ligands. One feature of the inhibitors is the shifted aqueous solubility (LogSw). The average calculated LogSw⁶⁵ of the active ligands is -7.2 , while the decoys have an average calculated LogSw of -6.6 . Another difference between actives and decoys is the average calculated nonpolar solvent accessible surface area; active ligands are on average 319 \AA^2 and the decoy ligands are 284 \AA^2 . The MM/GBSA rescoring calculation includes the solvent effect and captures the nonpolar interaction more accurately than the docking method, so the performance is more representative of actual binding. The more accurate solvent and nonpolar interaction calculations in the MM/GBSA rescoring method lead to a better enrichment performance for most of the kinases, where the enrichment factor improves from 1.39, 1.39, 1.36, 1.36, and 1.36 to 10.26, 9.74, 9.71, 7.28, and 4.92 from Vina docking to MM/GBSA rescoring at 0.5%, 1%, 2%, 5%, and 10% false positive rates, respectively. Another target egfr, epidermal growth factor receptor,⁶⁶ has similar solvent accessible characteristics in the active site as that of target src, which makes predominantly hydrophobic interactions with ligands in its ATP binding site. Therefore, the enrichment factor of target egfr is improved by MM/GBSA rescoring as compared with docking in a same way as target src.

Metalloenzymes. The DUD-E data set includes metalloenzymes targets angiotensin-converting enzyme (ace), adenosine deaminase (ada), catechol O-methyltransferase (comt), and phosphodiesterase 5A (pde5a). The overall enrichment performance of metalloenzymes is barely better than random selection, which is largely due to the presence of the metal ions in the active sites of the targets. For example, target ace (PDB ID: 3BKL)⁶⁷ has a large active site much like a dumbbell (Figure 9A). The two large binding pockets are connected by a narrow channel, where the X-ray ligand binds to the channel by coordinating its two hydroxyl groups to the zinc atom. This configuration is very challenging for docking. As shown in Figure 9B, the majority of the docking poses fall into either of the two large neighboring binding pockets. Most active ligands fail to coordinate with the zinc atom, which is crucial to binding in target ace. The ROC curves for target ace from both docking and free energy calculations (Figure 1S ace) show near random selection for active and decoy ligands. In the metalloenzymes, the metal ion plays an important role in the




Figure 9. Cross-section of the target ace active site: (A) crystal ligand; (B) docking poses. The zinc atom is colored in green. Only 20% actives are shown by random selection in the figure to improve the visibility.

binding affinity and geometry by coordinating with the ligand. Unless this coordination is properly represented in the interaction energy, the ligand binding will be wrong. For most docking methods, including AutoDock Vina, the simplified scoring functions cannot characterize the coordination and, thus, lead to poor enrichment performance in all four metalloenzymes in the DUD-E data set.

Folate Enzymes. The glycinamide ribonucleotide (GAR) transformylase is a folate-dependent enzyme within the *de novo* purine biosynthetic pathway.⁶⁸ The binding site for the folate cofactor moiety in human GAR transformylase (PDB ID: 1NJS),⁶⁹ target pur2, consists of three portions: the pteridine binding cleft, the catalytic site, and the formyl transfer region (Figure 10A). In addition to the cofactor binding site, there is a substrate-binding site adjacent to the catalytic sites. The pteridine binding cleft provides negatively charged residues, Glu141, Asp142, and Asp144, and rich carbonyl groups from the backbone of the protein to form the hydrogen bonds with the active ligands. Many positively charged residues, His108, His121, Lys170, and His174, present in the substrate-binding site can stabilize the negatively charged carboxyl groups of the active ligands. The same can also be found for Arg64 and Arg90 in the formyl transfer region. Thus, docking poses of the active ligands adopt two binding modes (Figure 10A). The majority of active ligands bind in the pteridine binding cleft, the catalytic site, and the substrate-binding site simultaneously. The rest of the ligands adopt the same binding mode as the folate cofactor moiety by binding in the pteridine binding cleft, the catalytic site, and the formyl transfer region simultaneously. The enrichment performance of target pur2 is excellent with AUC values of 0.922 for Vina docking and 0.996 for MM/GBSA




Figure 10. Target pur2. (A) Active site of target pur2 with 201 active ligands and an X-ray crystal ligand aligned in it. Carbon atoms of the active ligands are colored in cyan and those for X-ray crystal ligand are in yellow. (B) Normalized distribution of calculated LogP for active and decoy ligands. (C) Normalized distribution of calculated dipole for active and decoy ligands.

rescoring. The molecular properties of decoy ligands were designed to be consistent with active ligands. Specifically, molecular weight, calculated LogP, H-bond donors and acceptors, number of rotatable bonds, and net molecular charge of decoys were chosen to match active compounds. Comparing the molecular properties of active and decoy ligands (Table 2), there is no significant difference in terms of molecular weight, hydrogen bond donors and acceptors, number of rings, and the fractional polar solvent accessible surface area. The difference is shown in the net molecular charge, lipophilicity (LogP), and especially the dipole. Looking at the distributions of LogP, active ligands span from -5 to 1 with a peak around -2.5 , while decoys span a much wider range from -11 to 5 with a peak around 0.5 . The distributions of LogP for active and decoy ligands have good overlap between -5 to -1 . However, the distributions of the dipoles

Table 2. Molecular Properties of Active and Decoy Ligands from Target pur2

molecular property	actives	decoys
molecular weight	464 ± 23	418 ± 50
hydrogen bond donors	4.3 ± 0.6	3.1 ± 1.2
hydrogen bond acceptors	9.9 ± 1.1	7.6 ± 2.4
number of rings	2.9 ± 0.3	2.6 ± 0.9
fractional polar SASA	0.48 ± 0.05	0.41 ± 0.10
charge	−1.9 ± 0.3	−0.9 ± 0.6
LogP	−2.49 ± 0.99	−0.04 ± 2.14
dipole momentum (D)	61.7 ± 32.9	19.5 ± 12.1

for active and decoy ligands are both narrow. The dipoles of active ligands mainly range from 40 to 100 D while that of decoys range from 0 to 40 D. There is no significant overlap between the two distributions of dipoles, which indicates the molecular dipole is the main factor that differentiates the active and decoy ligands. These results are expected because the pteridine binding cleft has negatively charged residues and mostly binds with amine groups from ligands. On the other hand, the substrate-binding site and formyl transfer region have rich positively charged residues and mostly attract the negatively charged carbonyl groups of ligands. The distances between the pteridine binding cleft and either the substrate-binding site or formyl transfer region are large. Thus, the active ligands must have a large dipole in order to bind with such a large bipolar binding sites. Both Vina docking and MM/GBSA rescoring methods capture the molecular dipole momentum very well and, thus, yield excellent enrichment performance. MM/GBSA rescoring has slightly better performance because the method has a more accurate calculation of the electrostatic interaction.

Target dyr, human dihydrofolate reductase, also has a folate binding site,⁷⁰ which is a large bipolar binding site. Similar to target pur2, charged residues in the binding site have been shown to contribute significantly to electronic polarization of the folate ligand.⁷¹ Scrutinizing the molecular properties of the ligand, the average LogP for active and decoy ligands are 0.97 and 1.16. The distributions of LogP for active and decoy ligands resemble each other closely. However, the average dipole momentum for active and decoy ligands for target dyr are 30.52 and 13.02 D. Judging from the results of both target pur2 and dyr, one can conclude that the dipole momentum of the ligand is crucial to binding the folate enzymes, and both Vina docking and MM/GBSA methods capture the dipole accurately. One difference between target dyr and pur2 is that distributions of dipoles of active and decoy ligands for target dyr are not well separated as those distributions for target pur2. Thus, the enrichment performance of the target pur2 is better than that of target dyr.

Serine Protease. Serine proteases cleave peptide bonds in proteins, where serine serves as the nucleophile in the reaction.⁷² There are three binding pockets in the serine protease, S1, S2, and S3, as shown in Figure 11A. The catalytic triad, adjacent to the S2 binding pocket, consists of serine, histidine, and aspartic acid. Target try1, Trypsin I (PDB ID: 2AYW), is a prominent member of serine protease family.⁷³ The diaminemethyl group of the crystal ligand forms hydrogen bonds with Asp189 in the S1 binding pocket (Figure 11B). Many actives of target try1 contain amines or diaminemethyl groups, which form hydrogen bonds with Asp189. Active CHEMBL327331 is one such active, containing a diamine-




Figure 11. Target try1 with crystal ligand and Active CHEMBL327331: (A) crystal ligand; (B) crystal ligand in S1 binding pocket; (C) poses of Active CHEMBL327331 selected by docking and MM/GBSA rescoring. Carbon atoms of docking selected pose are colored in cyan and that for MM/GBSA rescoring are in magenta. (D) Active CHEMBL327331 in S1 binding pocket.

methyl group (Figure 11C), and docked into the S1 binding pocket as the crystal ligand (Figure 11D). However, the docking pose is not close enough for the ligand to form hydrogen bonds with Asp189, which causes the MM/GBSA rescoring method to drop this pose and select the pose with the diaminemethyl group exposed to the solvent. It is possible that the solvation model incorrectly overstabilizes the diaminemethyl group solvation versus the stabilization of hydrogen bonds to the target. Therefore, the MM/GBSA rescoring method picks the pose with the wrong binding mode. About 13% of the actives of target try1 have a similar problem as Active CHEMBL327331. In these cases, the MM/GBSA rescoring results in worse enrichment performance for target try1 when compared to docking. The AUC value of MM/GBSA is 0.63, which is smaller than that of Vina docking (0.78).

Nuclear Hormone Receptors. From the ROC plots (Supporting Information Figure 1S) and bar graphs of the AUC (Figure 4), the nuclear hormone receptors from the DUD-E data set have similar enrichment performance for docking and free energy rescoring. Peroxisome proliferator-activated receptors γ (target pparg) has almost identical ROC curves for Vina docking and MM/GBSA rescoring. However, MM/GBSA rescoring chooses only ~18% of the same poses as Vina docking. Nevertheless, most of the poses selected by the MM/GBSA rescoring closely resemble the poses selected by Vina docking. The main differences between poses selected by the MM/GBSA rescoring and Vina docking are often in the areas that are exposed to solvent. The normalized distributions of the MM/GBSA score for actives and decoys have similar shapes as

those from Vina score (Figure 12), which indicates that the MM/GBSA rescoring and Vina docking have similar enrichment performance for nuclear hormone receptors.




Figure 12. Normalized distribution of (A) Vina docking and (B) MM/GBSA rescoring score for active and decoy ligands.

Other Enzymes. *S*-Adenosylhomocysteine hydrolase (target sahh) catalyzes *S*-Adenosylhomocysteine to adenosine and homocysteine in the hydrolytic direction and catalyzes the reverse reaction in the synthesis direction.⁷⁴ The active site is a highly charged, tight binding pocket. As mentioned in the previous section, the Vina scoring function underestimates the repulsion terms. When the decoys were docked into the tight active site, their scores are unusually high. About 40% of the decoys have Vina scores better (less) than -8.0 kcal/mol. MM/GBSA rescoring yields relatively accurate binding affinity. More than 82% of the decoys were determined to be lower affinity binders by MM/GBSA rescoring when using the criterion of -30 kcal/mol for the MM/GBSA score. This also can be observed from the AUC values, where the AUC value of MM/GBSA (0.86) is much larger than that of Vina docking (0.56).

To summarize the target specificity, rescoring of the kinases, folate enzymes, reductases, phosphorylases, HIV-1 protease, HIV-1 reverse transcriptase, polymerase, and several other hydrolases improves the enrichment performance as compared to docking alone. For the metalloenzymes, although the rescoring can improve the enrichment performance, docking usually produces the wrong poses, which often makes the rescoring calculation unnecessary. The serine proteases should not be rescored because the enrichment performance of rescoring is worse than that of docking. Finally, there is no need to rescore the nuclear hormone receptors because there is not much gain in the enrichment performance.

What is Needed to Achieve Better Enrichment Performance? MM/GBSA rescoring is dependent on the

docking poses. Due to limited computer resources, only a few docking poses of the top resulting docking compounds can be rescored by MM/GBSA. In this study, we choose only the top 20 docking poses for each ligand. The MM/GBSA rescoring, either calculated from a “single-point” energy minimization or averaged from MD trajectory, is often limited to explore the energy landscape of binding and usually constrained to the local minima. Thus, MM/GBSA cannot improve the accuracy of the calculated binding energy if the selected docking poses for rescoring have the wrong binding modes. Metalloenzymes employed in this study fall into this category; the docking poses have the wrong binding modes, and MM/GBSA rescoring cannot improve the enrichment performance.

The docking scoring function usually sacrifices accuracy for calculation speed. For example, the Vina scoring function uses pure empirical terms to speed up the docking calculations.⁷⁵ The trade-off between the accuracy and calculation speed is subtle for MM/GBSA rescoring. The docking scoring function must pick poses with the correct binding mode for MM/GBSA rescoring. On average, the enrichment performance of Vina docking is good (as shown in the previous section and our previous study⁴³). In some cases, the Vina scoring function underestimates the repulsion term, which can be readily corrected by MM/GBSA rescoring. MM/GBSA rescoring better accounts for the hydrophobic effect by estimating it from the solvent accessible surface. Such a hydrophobic effect arises from solute-imposed constraints on the organization of water that is part of entropic effects. The polarizable effect is also very important in the binding affinity calculation. Upon binding, the partial charges of atoms in both ligand and target will redistribute,^{76,77} which can significantly affect binding. Unfortunately, the MM/GBSA rescoring uses fixed charge model and Vina scoring function uses empirical terms behaving similarly to fixed charge model, which do not account for the polarizable effect. Quantum-mechanics-based or polarizable-force-field-based docking can capture the polarizable effect in this case.^{77–81}

Solvent effects play an important role in binding affinity calculations. The standard Vina scoring function does not include solvation terms, which makes MM/GBSA rescoring particularly important to improve enrichment and obtain accurate binding affinity in cases where solvation plays a significant role. There are many examples in the DUD-E data set where ligands dock into the active site of solvent exposed targets. MM/GBSA is able to select the right poses with hydrophilic groups facing the solvent. Overall, MM/GBSA has a more accurate energy function than that of the Vina docking program. Most of the time MM/GBSA can pick the correct poses generated by Vina docking program.

How Many Poses Are Needed for Accurate Rescoring?

It is often the case that the best scoring docked pose produced by VinaLC does not correspond to the best ranked pose by MM/GBSA. Unfortunately, rescoring all poses produced by VinaLC can be very computationally expensive. In order to evaluate the optimal number of docked poses to move forward to rescoring, we saved the top 20 docked poses of each complex for MM/GBSA rescoring. In practice, we performed ~ 14 millions MM/GBSA energy minimization calculations for the whole DUD-E data set. With such a large number of calculations, we were able to statistically determine the optimal number of docking poses that should be kept for MM/GBSA rescoring. In the first approach, we found the docking ranks (ranging from 1 to 20) of the MM/GBSA-selected poses for all

0.7 million complexes. The 0.7 million MM/GBSA-selected poses were then binned according to their docking ranks. The percentages of MM/GBSA-selected poses in each bin were calculated and a cumulative percentage plot is shown in Figure 13A. Docking-selected poses are always ranked 1. As seen in




Figure 13. Determination of the optimal number of rescoring poses. (A) Cumulative percentage of MM/GBSA-selected poses versus their docking ranks. (B) Errors of $\Delta G_{\text{binding}}$ at different numbers of saved rescoring poses for actives and decoys, respectively. (C) Error percentages of $\Delta G_{\text{binding}}$ at different numbers of saved rescoring poses for actives and decoys, respectively.

the Figure 13A, only ~17% of complexes have identical docking- and MM/GBSA-selected poses. If the top 5 docking poses are kept, ~51% of complexes find the lowest MM/GBSA binding free energies among the top 20 poses. If the top 10 poses are kept, ~75% of complexes find the lowest values. Approximately 90% of complexes find the lowest values, if the top 15 poses are kept. Another approach is to calculate the average difference (i.e., error) between the minimal binding free energies of the top M and the top 20 docking poses, where M could be 1, 5, 10, 15, and 20.

$$\text{Error}(M) = \frac{\sum_{i=1}^N |\Delta G_{\text{binding}}^{\text{min}}(M) - \Delta G_{\text{binding}}^{\text{min}}(20)|}{N}$$

$\Delta G_{\text{binding}}^{\text{min}}(M)$ is the minimal binding free energy of top M poses calculated by MM/GBSA rescoring. N is the number of complexes. The error(M) values are calculated for the actives and decoys separately and shown in Figure 13B. The trends of the lines for actives and decoys are similar. The errors at 1 are significantly large for both actives (9.5 kcal/mol) and decoys (9.8 kcal/mol). The lines become flat at the range from 5 to 10 poses. The errors of the free energy are 2.7 kcal/mol for actives and 2.8 kcal/mol for decoys at 5 poses. The errors of the free energy are 1.0 kcal/mol for actives and 1.1 kcal/mol for decoys at 10 poses. The errors of the free energy for both actives and decoys at 15 poses are 0.3 kcal/mol, which is fairly small as the average binding free energy for actives is about -30 kcal/mol. Error(M) values are the absolute errors, and we also calculated the average error percentages by equation:

$$\begin{aligned} \text{Error percentage}(M) &= \frac{\sum_{i=1}^N |(\Delta G_{\text{binding}}^{\text{min}}(M) - \Delta G_{\text{binding}}^{\text{min}}(20)) / \Delta G_{\text{binding}}^{\text{min}}(20)|}{N} \end{aligned}$$

The error percentages were plotted as shown in Figure 13C. When only one docking pose is saved for rescoring, the error percentages are 33% and 35% for actives and decoys, respectively. If the top 5 docking poses are rescored, the error percentages drop drastically to 10% and 12%. If the top 10 docking poses are rescored, the error percentages decrease to 4% for both actives and decoys. If the top 15 docking poses are rescored, the number drops to 1%. The lines of error(M) and error percentage(M) drop significantly from 1 to 5 as compare to the line of cumulative percentage because it is quite often that the second or third (or more) best rescoring values are close to the best one. Picking the second best pose other than the best one may be acceptable if their binding free energies are similar. Therefore, in terms of determining the optimal number of docking poses, error(M) and error percentage(M) values are better than cumulative percentage values. Judging from all the above results, we suggest keeping at least the top 5 poses for the MM/GBSA rescoring. Ideally, we suggest keeping the top 10 docking poses to achieve good accuracy.

Why Parallel Programming Is Essential for the Docking and Rescoring Pipeline? High throughput virtual screening of large databases is a very popular practice in computer-aided drug design. However, limited computational resources can cap the database size that can be screened in practice. The common practices of computer-aided drug design employed in pharmaceutical companies are still dominated by personal computers and midsize clusters with hundreds of CPU core. Supercomputers, although mature and popular in the field of molecular simulations and modeling, are seldom used in the *in-silico* drug design process. Applying high performance computing (HPC) toward drug design could be a game-changing strategy for pharmaceutical companies. For a typical example in the DUD-E data set, the time scales of a target of ~4000 atoms and ~40 000 ligands running through the pipeline are shown in Figure 2. The process, if on a single CPU, takes ~10 min to prepare the protein target, ~4 days to prepare the ligands, ~1 month to dock the ligands into the target, and ~10 years to rescore the top 20 docking poses of all ligands. In contrast, the same process on HPC takes ~1 h on

100 CPUs to prepare the ligands, ~1 h on 700 CPUs to carry out docking calculations, and ~5 h on 15 000 CPUs to rescore the docking poses, totaling ~8 h. HPC makes the screening of large databases practical and fits the fast pace of research and development in pharmaceutical companies. For example, a useful procedure is to screen 30 million compounds from the ZINC database against one therapeutic target using such a pipeline. One usually can down-select the 30 million compounds to several hundred thousands compounds, according to the rankings from docking calculations. The down-selected compounds then are rescored to further down-select for a drug lead. The whole procedure only takes days to finish on HPC but would be impractical to complete on a PC.

CONCLUSION

On average, the enrichment performance is improved by MM/GBSA rescoring. The average AUC value of ROC plots for MM/GBSA is larger than that of Vina docking. The early recovery of actives for MM/GBSA rescoring is consistently better than that of docking. However, the enrichment performance is target-dependent. MM/GBSA rescoring has better performance for folate enzyme, kinases, reductases, phosphorylases, HIV-1 protease, HIV-1 reverse transcriptase, polymerase, and several other hydrolases.

MM/GBSA rescoring highly depends on the docking method to generate the poses with correct binding modes. As shown in the case of metalloenzymes, MM/GBSA rescoring cannot improve the accuracy, if all the top ranked docking poses for rescoring have the wrong binding modes, since the docking pose is the starting structure for the MM/GBSA calculation. The docking method sacrifices accuracy in the energy function for calculation speed. MM/GBSA has much more accurate energy functions to account for solvent effects, hydrophobic/entropic effects, electrostatic interaction, hydrogen bonding, and van der Waals interactions. However, the polarizable effect, one of the important factors in binding, is not taken into account for MM/GBSA and conventional docking methods. The serine proteases and nuclear hormone receptors should be not be rescored because the enrichment performance of rescoring on serine proteases is worse than that of docking, and rescoring on nuclear hormone receptors does not gain better performance. Determined by the statistical methods, we find the minimal number of docking poses to keep for MM/GBSA rescoring is 5, and the optimal number is 10.

To implement a docking and rescoring pipeline, such that better lead compounds can be discovered, requires parallel processing on HPC to screen millions of compounds. Applying HPC to *in-silico* drug design could be a game-changing strategy for pharmaceutical companies. The screening of large databases is not practical and may be impossible to complete on a PC but is attainable within a day when implemented in parallel on HPC machines. Thus, parallel docking and rescoring can impact daily decisions in drug design programs.

ASSOCIATED CONTENT

Supporting Information

Figure S1: ROC plots of 38 DUD-E targets to demonstrate the enrichment performance of docking and MM/GBSA rescoring. Table S1: AUC values of the 38 DUD-E targets for Vina docking and MM/GBSA rescoring. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: lightstone1@llnl.gov.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank Livermore Computing for the computer time and Laboratory Directed Research and Development for funding (12-SI-004). This work was performed under the auspices of the United States Department of Energy by the Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. Release Number LLNL-JRNL-642881.

REFERENCES

- (1) Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nat. Rev. Drug Discov.* **2004**, *3*, 935–949.
- (2) Jorgensen, W. L. The many roles of computation in drug discovery. *Science* **2004**, *303*, 1813–1818.
- (3) Smith, R. D.; Dunbar, J. B.; Ung, P. M. U.; Esposito, E. X.; Yang, C. Y.; Wang, S. M.; Carlson, H. A. CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions. *J. Chem. Inf. Model.* **2011**, *51*, 2115–2131.
- (4) Halperin, I.; Ma, B. Y.; Wolfson, H.; Nussinov, R. Principles of docking: An overview of search algorithms and a guide to scoring functions. *Proteins-Struct. Funct. Genet.* **2002**, *47*, 409–443.
- (5) Wang, R. X.; Lu, Y. P.; Wang, S. M. Comparative evaluation of 11 scoring functions for molecular docking. *J. Med. Chem.* **2003**, *46*, 2287–2303.
- (6) Raha, K.; Peters, M. B.; Wang, B.; Yu, N.; WollaCott, A. M.; Westerhoff, L. M.; Merz, K. M. The role of quantum mechanics in structure-based drug design. *Drug Discov. Today* **2007**, *12*, 725–731.
- (7) Sousa, S. F.; Fernandes, P. A.; Ramos, M. J. Protein-ligand docking: Current status and future challenges. *Proteins-Struct. Funct. Bioinf.* **2006**, *65*, 15–26.
- (8) Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C. R. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. *Br. J. Pharmacol.* **2008**, *153*, S7–S26.
- (9) Rastelli, G.; Del Rio, A.; Degliesposti, G.; Sgobba, M. Fast and Accurate Predictions of Binding Free Energies Using MM-PBSA and MM-GBSA. *J. Comput. Chem.* **2010**, *31*, 797–810.
- (10) Guimaraes, C. R. W.; Cardozo, M. MM-GB/SA rescoring of docking poses in structure-based lead optimization. *J. Chem. Inf. Model.* **2008**, *48*, 958–970.
- (11) Thompson, D. C.; Humblet, C.; Joseph-McCarthy, D. Investigation of MM-PBSA rescoring of docking poses. *J. Chem. Inf. Model.* **2008**, *48*, 1081–1091.
- (12) Zhang, X. H.; Gibbs, A. C.; Reynolds, C. H.; Peters, M. B.; Westerhoff, L. M. Quantum Mechanical Pairwise Decomposition Analysis of Protein Kinase B Inhibitors: Validating a New Tool for Guiding Drug Design. *J. Chem. Inf. Model.* **2010**, *50*, 651–661.
- (13) Wong, S. E.; Lightstone, F. C. Accounting for water molecules in drug design. *Expert Opin. Drug Discov.* **2011**, *6*, 65–74.
- (14) Yang, Y.; Lightstone, F. C.; Wong, S. E. Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: the use of WaterMap. *Expert Opin. Drug Discov.* **2013**, *8*, 277–287.
- (15) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* **1983**, *79*, 926–935.
- (16) Roux, B.; Simonson, T. Implicit solvent models. *Biophys. Chem.* **1999**, *78*, 1–20.
- (17) Massova, I.; Kollman, P. A. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. *Perspect. Drug Discov. Des.* **2000**, *18*, 113–135.

- (18) Kuhn, B.; Gerber, P.; Schulz-Gasch, T.; Stahl, M. Validation and use of the MM-PBSA approach for drug discovery. *J. Med. Chem.* **2005**, *48*, 4040–4048.
- (19) Gohlke, H.; Kiel, C.; Case, D. A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RaIGDS complexes. *J. Mol. Biol.* **2003**, *330*, 891–913.
- (20) Zhang, X.; Bruice, T. C. Complexation of single strand telomere and telomerase RNA template polyanions by deoxyribonucleic guanidine (DNG) polycations: Plausible anticancer agents. *Biorg. Med. Chem. Lett.* **2008**, *18*, 665–669.
- (21) Case, D. A.; Cheatham, T. E., 3rd; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs. *J. Comput. Chem.* **2005**, *26*, 1668–88.
- (22) Miller, B. R.; McGee, T. D.; Swails, J. M.; Homeyer, N.; Gohlke, H.; Roitberg, A. E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. *J. Chem. Theory Comput.* **2012**, *8*, 3314–3321.
- (23) Brooks, B. R.; Brooks, C. L.; Mackerell, A. D.; Nilsson, L.; Petrella, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caffisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M. CHARMM: The biomolecular simulation program. *J. Comput. Chem.* **2009**, *30*, 1545–1614.
- (24) Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. *J. Chem. Theory Comput.* **2008**, *4*, 435–447.
- (25) Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S. H.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. *Acc. Chem. Res.* **2000**, *33*, 889–897.
- (26) Baker, N. A. Improving implicit solvent simulations: a Poisson-centric view. *Curr. Opin. Struct. Biol.* **2005**, *15*, 137–143.
- (27) Feig, M.; Brooks, C. L. Recent advances in the development and application of implicit solvent models in biomolecule simulations. *Curr. Opin. Struct. Biol.* **2004**, *14*, 217–224.
- (28) Chen, J. H.; Brooks, C. L.; Khandogin, J. Recent advances in implicit solvent-based methods for biomolecular simulations. *Curr. Opin. Struct. Biol.* **2008**, *18*, 140–148.
- (29) Lu, B. Z.; Zhou, Y. C.; Holst, M. J.; McCammon, J. A. Recent progress in numerical methods for the Poisson-Boltzmann equation in biophysical applications. *Commun. Comput. Phys.* **2008**, *3*, 973–1009.
- (30) Bruice, T. C. Computational approaches: Reaction trajectories, structures, and atomic motions. Enzyme reactions and proficiency. *Chem. Rev.* **2006**, *106*, 3119–3139.
- (31) Mongan, J.; Case, D. A. Biomolecular simulations at constant pH. *Curr. Opin. Struct. Biol.* **2005**, *15*, 157–163.
- (32) Chen, J. H.; Im, W. P.; Brooks, C. L. Balancing solvation and intramolecular interactions: Toward a consistent generalized born force field. *J. Am. Chem. Soc.* **2006**, *128*, 3728–3736.
- (33) Kelly, C. P.; Cramer, C. J.; Truhlar, D. G. Adding explicit solvent molecules to continuum solvent calculations for the calculation of aqueous acid dissociation constants. *J. Phys. Chem. A* **2006**, *110*, 2493–2499.
- (34) Shivakumar, D.; Deng, Y. Q.; Roux, B. Computations of Absolute Solvation Free Energies of Small Molecules Using Explicit and Implicit Solvent Model. *J. Chem. Theory Comput.* **2009**, *5*, 919–930.
- (35) Mongan, J.; Simmerling, C.; McCammon, J. A.; Case, D. A.; Onufriev, A. Generalized Born model with a simple, robust molecular volume correction. *J. Chem. Theory Comput.* **2007**, *3*, 156–169.
- (36) Labute, P. The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. *J. Comput. Chem.* **2008**, *29*, 1693–1698.
- (37) Onufriev, A.; Bashford, D.; Case, D. A. Exploring protein native states and large-scale conformational changes with a modified generalized born model. *Proteins-Struct. Funct. Bioinf.* **2004**, *55*, 383–394.
- (38) Hou, T. J.; Wang, J. M.; Li, Y. Y.; Wang, W. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. I. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations. *J. Chem. Inf. Model.* **2011**, *51*, 69–82.
- (39) Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. *J. Comput. Chem.* **2011**, *32*, 866–877.
- (40) Xu, L.; Sun, H.; Li, Y.; Wang, J.; Hou, T. Assessing the Performance of MM/PBSA and MM/GBSA Methods. 3. The Impact of Force Fields and Ligand Charge Models. *J. Phys. Chem. B* **2013**, *117*, 8408–8421.
- (41) Huang, N.; Kalyanaraman, C.; Irwin, J. J.; Jacobson, M. P. Physics-based scoring of protein-ligand complexes: Enrichment of known inhibitors in large-scale virtual screening. *J. Chem. Inf. Model.* **2006**, *46*, 243–253.
- (42) Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. *J. Med. Chem.* **2012**, *55*, 6582–6594.
- (43) Zhang, X.; Wong, S. E.; Lightstone, F. C. Message passing interface and multithreading hybrid for parallel molecular docking of large databases on petascale high performance computing machines. *J. Comput. Chem.* **2013**, *34*, 915–927.
- (44) Nilmeier, J. P.; Kirshner, D. A.; Wong, S. E.; Lightstone, F. C. Rapid Catalytic Template Searching as an Enzyme Function Prediction Procedure. *PLoS ONE* **2013**, *8*, e62535.
- (45) Kirshner, D. A.; Nilmeier, J. P.; Lightstone, F. C. Catalytic site identification—a web server to identify catalytic site structural matches throughout PDB. *Nucleic Acids Res.* **2013**, *41*, W256–W265.
- (46) Richards, F. M. Areas, volumes, packing, and protein-structure. *Annu. Rev. Biophys. Bioeng.* **1977**, *6*, 151–176.
- (47) Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. *J. Mol. Biol.* **1982**, *161*, 269–288.
- (48) Ponder, J. W.; Case, D. A. Force fields for protein simulations. *Protein Simulations* **2003**, *66*, 27–85.
- (49) Wang, J. M.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. *J. Comput. Chem.* **2004**, *25*, 1157–1174.
- (50) Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations. *J. Mol. Graph. Model.* **2006**, *25*, 247–260.
- (51) Jakalian, A.; Bush, B. L.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic Charges. AM1-BCC model: I. Method. *J. Comput. Chem.* **2000**, *21*, 132–146.
- (52) SLURM Simple Linux Utility for Resource Management, <https://computing.lln.gov/linux/slurm/> (accessed Dec 30, 2013).
- (53) Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking. *J. Med. Chem.* **2006**, *49*, 6789–6801.
- (54) Pearlman, D. A.; Charifson, P. S. Improved scoring of ligand-protein interactions using OWFEG free energy grids. *J. Med. Chem.* **2001**, *44*, 502–511.
- (55) Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *J. Med. Chem.* **2004**, *47*, 1750–1759.
- (56) Cross, J. B.; Thompson, D. C.; Rai, B. K.; Baber, J. C.; Fan, K. Y.; Hu, Y. B.; Humblet, C. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy. *J. Chem. Inf. Model.* **2009**, *49*, 1455–1474.
- (57) Swets, J. A.; Dawes, R. M.; Monahan, J. Better decisions through science. *Sci. Am.* **2000**, *283*, 82–87.

- (58) Kellenberger, E.; Foata, N.; Rognan, D. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: Methods and problems. *J. Chem. Inf. Model.* **2008**, *48*, 1014–1025.
- (59) Jain, A. N. Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition. *J. Comput. Aided Mol. Des.* **2000**, *14*, 199–213.
- (60) Hayes, J. M.; Skamnaki, V. T.; Archontis, G.; Lamprakis, C.; Sarrou, J.; Bischler, N.; Skaltsounis, A. L.; Zographos, S. E.; Oikonomakos, N. G. Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: The role of water molecules examined. *Proteins-Struct. Funct. Bioinf.* **2011**, *79*, 703–719.
- (61) Greenidge, P. A.; Kramer, C.; Mozziconacci, J. C.; Wolf, R. M. MM/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement. *J. Chem. Inf. Model.* **2013**, *53*, 201–209.
- (62) Graves, A. P.; Shivakumar, D. M.; Boyce, S. E.; Jacobson, M. P.; Case, D. A.; Shoichet, B. K. Rescoring docking hit lists for model cavity sites: Predictions and experimental testing. *J. Mol. Biol.* **2008**, *377*, 914–934.
- (63) Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms. *Chem. Biol.* **2004**, *11*, 775–785.
- (64) Dar, A. C.; Lopez, M. S.; Shokat, K. M. Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation. *Chem. Biol.* **2008**, *15*, 1015–1022.
- (65) Cheng, A. L.; Merz, K. M. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. *J. Med. Chem.* **2003**, *46*, 3572–3580.
- (66) Xu, G. Z.; Abad, M. C.; Connolly, P. J.; Neeper, M. P.; Struble, G. T.; Springer, B. A.; Emanuel, S. L.; Pandey, N.; Gruninger, R. H.; Adams, M.; Moreno-Mazza, S.; Fuentes-Pesquera, A. R.; Middleton, S. A. 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. *Biorg. Med. Chem. Lett.* **2008**, *18*, 4615–4619.
- (67) Watermeyer, J. M.; Kroger, W. L.; O'Neill, H. G.; Sewell, B. T.; Sturrock, E. D. Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme. *Biochemistry (Mosc.)* **2008**, *47*, 5942–5950.
- (68) Inglese, J.; Johnson, D. L.; Shiau, A.; Smith, J. M.; Benkovic, S. J. Subcloning, characterization, and affinity labeling of Escherichia coli glycineamide ribonucleotide transformylase. *Biochemistry (Mosc.)* **1990**, *29*, 1436–1443.
- (69) Zhang, Y.; Desharnais, J.; Marsilje, T. H.; Li, C. L.; Hedrick, M. P.; Gooljarsingh, L. T.; Tavassoli, A.; Benkovic, S. J.; Olson, A. J.; Boger, D. L.; Wilson, I. A. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR tase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. *Biochemistry (Mosc.)* **2003**, *42*, 6043–6056.
- (70) Cody, V.; Piraino, J.; Pace, J.; Li, W.; Gangjee, A. Preferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the E and Z isomers of a series of 5-substituted 2,4-diaminofuro 2,3-d pyrimidines as ternary complexes with NADPH and human dihydrofolate reductase. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **2010**, *66*, 1271–1277.
- (71) Bajorath, J.; Kitson, D. H.; Kraut, J.; Hagler, A. T. The electrostatic potential of Escherichia coli dihydrofolate reductase. *Proteins-Struct. Funct. Genet.* **1991**, *11*, 1–12.
- (72) Hedstrom, L. Serine Protease Mechanism and Specificity. *Chem. Rev.* **2002**, *102*, 4501–4524.
- (73) Sherawat, M.; Kaur, P.; Perbandt, M.; Betzel, C.; Slusarchyk, W. A.; Bisacchi, G. S.; Chang, C. Y.; Jacobson, B. L.; Einspahr, H. M.; Singh, T. P. Structure of the complex of trypsin with a highly potent synthetic inhibitor at 0.97 angstrom resolution. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **2007**, *63*, 500–507.
- (74) Yang, X. D.; Hu, Y. B.; Yin, D. H.; Turner, M. A.; Wang, M.; Borchardt, R. T.; Howell, P. L.; Kuczera, K.; Schowen, R. L. Catalytic strategy of S-adenosyl-L-homocysteine hydrolase: Transition-state stabilization and the avoidance of abortive reactions. *Biochemistry (Mosc.)* **2003**, *42*, 1900–1909.
- (75) Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461.
- (76) Jiao, D.; Golubkov, P. A.; Darden, T. A.; Ren, P. Calculation of protein-ligand binding free energy by using a polarizable potential. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 6290–6295.
- (77) Maple, J. R.; Cao, Y. X.; Damm, W. G.; Halgren, T. A.; Kaminski, G. A.; Zhang, L. Y.; Friesner, R. A. A polarizable force field and continuum solvation methodology for modeling of protein-ligand interactions. *J. Chem. Theory Comput.* **2005**, *1*, 694–715.
- (78) Raha, K.; Merz, K. M. Large-scale validation of a quantum mechanics based scoring function: Predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes. *J. Med. Chem.* **2005**, *48*, 4558–4575.
- (79) Kantardjiev, A. A. Quantum.Ligand.Dock: protein-ligand docking with quantum entanglement refinement on a GPU system. *Nucleic Acids Res.* **2012**, *40*, W415–W422.
- (80) Gresh, N. Development, validation, and applications of anisotropic polarizable molecular mechanics to study ligand and drug-receptor interactions. *Curr. Pharm. Des.* **2006**, *12*, 2121–2158.
- (81) Wang, J. M.; Cieplak, P.; Li, J.; Hou, T. J.; Luo, R.; Duan, Y. Development of Polarizable Models for Molecular Mechanical Calculations I: Parameterization of Atomic Polarizability. *J. Phys. Chem. B* **2011**, *115*, 3091–3099.